Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | BRAF |
Variant | R188L |
Impact List | missense |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | BRAF R188L lies within the RBD domain of the Braf protein (UniProt.org). R188L is predicted to lead to a loss of Braf protein function as indicated by failure to restore transendothelial electrical resistance and Erk and cofilin phosphorylation in BRAF-null cells in culture (PMID: 30828992), and results in loss of Raf dimerization (PMID: 20141835, PMID: 22926515) and Ras interaction (PMID: 36347258), leading to reduced or loss of transforming activity when combined with class 1/2 or class 3 Braf mutations in cultured cells (PMID: 36347258). |
Associated Drug Resistance | |
Category Variants Paths |
BRAF mutant BRAF inact mut BRAF R188L |
Transcript | NM_004333.6 |
gDNA | chr7:g.140808937_140808938delAGinsCT |
cDNA | c.562_563delAGinsCT |
Protein | p.R188L |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_047420769.1 | chr7:g.140808937_140808938delAGinsCT | c.562_563delAGinsCT | p.R188L | RefSeq | GRCh38/hg38 |
NM_001374258.1 | chr7:g.140808937_140808938delAGinsCT | c.562_563delAGinsCT | p.R188L | RefSeq | GRCh38/hg38 |
NM_004333.6 | chr7:g.140808937_140808938delAGinsCT | c.562_563delAGinsCT | p.R188L | RefSeq | GRCh38/hg38 |
NM_001378468.1 | chr7:g.140808937_140808938delAGinsCT | c.562_563delAGinsCT | p.R188L | RefSeq | GRCh38/hg38 |
NM_004333.5 | chr7:g.140808937_140808938delAGinsCT | c.562_563delAGinsCT | p.R188L | RefSeq | GRCh38/hg38 |
NM_001354609.1 | chr7:g.140808937_140808938delAGinsCT | c.562_563delAGinsCT | p.R188L | RefSeq | GRCh38/hg38 |
NM_001378467.1 | chr7:g.140808937_140808938delAGinsCT | c.562_563delAGinsCT | p.R188L | RefSeq | GRCh38/hg38 |
NM_001354609.2 | chr7:g.140808937_140808938delAGinsCT | c.562_563delAGinsCT | p.R188L | RefSeq | GRCh38/hg38 |
NM_001378469.1 | chr7:g.140808937_140808938delAGinsCT | c.562_563delAGinsCT | p.R188L | RefSeq | GRCh38/hg38 |
XM_047420768.1 | chr7:g.140808937_140808938delAGinsCT | c.562_563delAGinsCT | p.R188L | RefSeq | GRCh38/hg38 |
XM_047420767.1 | chr7:g.140808937_140808938delAGinsCT | c.562_563delAGinsCT | p.R188L | RefSeq | GRCh38/hg38 |
XM_017012558.1 | chr7:g.140808937_140808938delAGinsCT | c.562_563delAGinsCT | p.R188L | RefSeq | GRCh38/hg38 |
NM_001378474.1 | chr7:g.140808937_140808938delAGinsCT | c.562_563delAGinsCT | p.R188L | RefSeq | GRCh38/hg38 |
NM_001378471.1 | chr7:g.140808937_140808938delAGinsCT | c.562_563delAGinsCT | p.R188L | RefSeq | GRCh38/hg38 |
NM_001374244.1 | chr7:g.140808937_140808938delAGinsCT | c.562_563delAGinsCT | p.R188L | RefSeq | GRCh38/hg38 |
XM_017012559.1 | chr7:g.140808937_140808938delAGinsCT | c.562_563delAGinsCT | p.R188L | RefSeq | GRCh38/hg38 |
XM_017012559.2 | chr7:g.140808937_140808938delAGinsCT | c.562_563delAGinsCT | p.R188L | RefSeq | GRCh38/hg38 |
XM_047420770.1 | chr7:g.140783058_140783059delAGinsCT | c.562_563delAGinsCT | p.R188L | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|